CEO Dr. Hanai and COO Dr. Miyamoto

The Kyowa Kirin Group provides high-quality products and services that meet various customer needs by leveraging its unique business base with different fields of the discovery of pharmaceutical products, biosimilars, and bio-chemicals, all working in close cooperation.

At the core of the group, Kyowa Kirin has a business vision where it will be a Japan-based Global Specialty Pharmaceutical Company contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by state-of-the art antibody technologies.
To realize our vision, we started promoting the selection and concentration of our businesses in the year 2008 and established a globally unique business base. Through the 2016–2020 Mid-Term Business Plan, we aim to further enhance and expand our base and become a leading, Japan-based R&D type life science company globally with the help of the “Leaping forward for GSP.”

As the Kyowa Kirin Group, we also believe that we could create another “new value” through the cooperation with the other Kirin Group companies.

We shall pursue sustainable growth by getting our collective act together as the Kyowa Kirin Group, so please look forward to that.



Director of the Board, Chairman
Nobuo Hanai

Kyowa Kirin continuously works on research to discover new drugs by taking advantage of the state-of-the-art biotechnologies in the four key areas of oncology, nephrology, immunology/allergy, and the central nervous system under the management philosophy that “the Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.”

Creating new value is essential for sustainable growth. We have been working on open innovation through collaboration with academia and other sectors for more than 20 years to provide “new value.” We will continue to develop revolutionary new drugs by organically connecting expertise and know-how inside as well as outside the company.
We will be able to deliver new drugs under the KYOWA KIRIN brand to patients in Europe and the U.S. and other overseas markets during the period of the current Mid-Term Business Plan. We have a renewed sense that we have been steadily growing into one of the few companies in the world that has its own distinctive value.

Combining individual strengths of all our employees, we will continue to contribute to the health and well-being of people around the world. We look forward to your ongoing support in our endeavors.



Executive Director of the Board
President and Chief Executive Officer
Masashi Miyamoto